Connor, Clark & Lunn Investment Management (CC&L)’s Royalty Pharma RPRX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-166,984	Closed	-$5.89M	–	1753
2025 Q3	$5.89M	Buy	166,984 +149,618	+862%	+$5.42M	0.02%	537
2025 Q2	$626K	Buy	+17,366	New	+$575K	﹤0.01%	1189
2022 Q4	–	Sell	-39,873	Closed	-$1.6M	–	1397
2022 Q3	$1.6M	Buy	39,873 +24,128	+153%	+$1.03M	0.01%	544
2022 Q2	$662K	Buy	+15,745	New	+$645K	﹤0.01%	713

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s RPRX Position: Q4 2025 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Royalty Pharma (RPRX) in Q4 2025, closing a stake of 166,984 shares — an estimated $5.89M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in RPRX in Q2 2022 and held it in 4 quarters. The position peaked at $5.89M in Q3 2025. 539 funds tracked by Wall St. Rank hold RPRX as of Q4 2025.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Royalty Pharma position as of Q4 2025 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 166,984 Royalty Pharma shares in Q4 2025, an estimated $5.89M.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Royalty Pharma in Q2 2022 and held it in 4 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Royalty Pharma position peaked at $5.89M in Q3 2025.
539 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2025.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2025, filed 10 Feb 2026.